Rhenman & Partners Asset Management Ab Janux Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.01 Billion
- Q2 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 106,847 shares of JANX stock, worth $5.77 Million. This represents 0.44% of its overall portfolio holdings.
Number of Shares
106,847
Previous 104,500
2.25%
Holding current value
$5.77 Million
Previous $3.93 Million
13.75%
% of portfolio
0.44%
Previous 0.38%
Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
158Shares Held
37.2MCall Options Held
70.4KPut Options Held
101K-
Ra Capital Management, L.P. Boston, MA9.17MShares$495 Million5.79% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.98MShares$161 Million3.01% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$127 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.33MShares$126 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X01.8MShares$97.3 Million0.04% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.25B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...